HMOX1 and Duchenne muscular dystrophy: HO-1 has been proposed as a target for DMD treatment, primarily due to its anti-inflammatory and cytoprotective functions, which derive from the degradation of pro-oxidant heme and the important roles of its metabolites [31, 32].